Sets the stage for advances in drug discovery using the latest enzyme technology
Reviewing new and emerging applications of enzyme technology in drug discovery, this book highlights some of the most promising areas of pharmaceutical and biotechnology research. It covers enzyme assay technology, utilization of enzymology for prodrug design, and the application of enzymes as therapeutic agents. Expert reviews highlight how our latest understanding of enzymology is used to develop new practical applications in drug discovery and design.
Filled with case studies, Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agents enables readers to better understand the diverse functions of enzymes and master specific applications in drug discovery research. In addition to small molecule drug discovery, the book explores new developments in enzymes as therapeutic agents for genetic disorders.
- Section A, Enzymes Essential Workhorses in Pharmaceutical Research, offers support in selecting the best enzyme targets for drug discovery, designing enzyme inhibitors for therapeutic agents, and evaluating selective enzyme inhibitors.
- Section B, Enzymes Indispensable Tools for Improving Druggability, sets forth the principles alongside real-world examples of exploiting specific properties of enzymes to design successful prodrugs.
- Section C, Enzymes Powerful Weapons for Correcting Nature's Errors, provides new insights on applying enzymes as therapeutic agents or diagnostic tools to treat genetic disorders.
Chapters are contributed by leading experts from around the world. Their contributions are based on a thorough review of the current literature as well as their own research.
Reviewing our latest understanding of the nature of enzymes and their role in drug discovery, this book is recommended for researchers in pharmaceuticals and biotechnology as well as for researchers in enzymology, biochemistry, molecular biology, and medicinal chemistry.
Inhaltsverzeichnis
1;Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agents;5 2;Copyright ;6 3;Contents;7 4;Contributors;9 5;Preface;11 6;PART A ENZYMES ESSENTIAL WORKHORSES IN PHARMACEUTICAL RESEARCH;15 6.1;1 ASSAY TECHNOLOGIES FOR PROTEASES ;17 6.1.1;I. INTRODUCTION;17 6.1.2;II. PROTEASE ACTIVITY ASSAYS;21 6.1.3;III. ASSAYS FOR SOME CLINICALLY SIGNIFICANT PROTEASES;37 6.1.4;IV. COMPUTATIONAL APPROACHES FOR PROTEASE IDENTIFICATION AND CHARACTERIZATION;49 6.2;2 DISCOVERY AND DEVELOPMENT OF ISOZYME-SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM ;69 6.2.1;I. INTRODUCTION;69 6.2.2;II. DIACYLGLYCEROL ACYLTRANSFERASE (DGAT);74 6.2.3;III. ACYL-COA: CHOLESTEROL ACYLTRANSFERASE (ACAT);77 6.2.4;IV. CONCLUSIONS AND FUTURE PERSPECTIVES;84 6.2.5;References;84 6.3;3 COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT ;95 6.3.1;I. INTRODUCTION;95 6.3.2;II. MECHANISM OF INHIBITION: MECHANISTIC TYPES BY PRINCIPLE OF INHIBITION;97 6.3.3;III. KINETICS: CONCEPTUAL AND EXPERIMENTAL CONSIDERATIONS;102 6.3.4;IV. SPECIFIC EXAMPLES OF COVALENT INHIBITORS;109 6.3.5;V. COVALENT ADDUCT WITH COFACTOR ALONE;127 6.3.6;VI. FULLY IRREVERSIBLE NONCOVALENT INHIBITION;128 6.3.7;VII. REVERSIBILITY AND DRUG RESISTANCE;129 6.3.8;VIII. PSEUDO-IRREVERSIBLE INHIBITION;129 6.3.9;IX. IRREVERSIBLE INHIBITORS AS TOOLS: ACTIVITY-BASED PROTEOMICS (ABP);130 6.3.10;X. MBI OF CYPs;131 6.3.11;XI. THE PROBLEM OF HAPTENATION;132 6.3.12;XII. CONCLUSION;133 6.3.13;References;134 6.4;4 PRECLINOMICS: ENZYME ASSAYS AND RODENT MODELS FOR METABOLIC DISEASES ;145 6.4.1;I. INTRODUCTION;145 6.4.2;II. EVOLVING ENZYME ASSAYS;146 6.4.3;III. DEVELOPING NEW RAT MODEL FOR METABOLIC DISEASES;153 6.4.4;IV. ZDSD RAT: EVALUATING CURRENT DRUGS;157 6.4.5;V. EXISTING RODENT MODELS: ESTABLISHING POSITIVE CONTROLS;161 6.4.6;VI. EXISTING RODENT MODELS AND ONE CANCER PATIENT: TESTING NUTRITIONAL SUPPLEMENT (ALKA VITA);164 6.4.7;VII. CONCLUDING REMARKS;171 6.4.8;References;174 7;PART B ENZYMES INDISPENSABLE TOOLS FOR IMPROVING DRUGG
ABILITY;177 7.1;5 ENZYMES AND TARGETED ACTIVATION OF PRODRUGS ;179 7.1.1;I. INTRODUCTION;179 7.1.2;II. ENDOGENOUS ENZYMES;185 7.1.3;III. NONENDOGENOUS ENZYMES;219 7.1.4;IV. CONCLUDING REMARKS;233 7.1.5;References;233 7.2;6 EVOLUTION OF AN ORALLY ACTIVE PRODRUG OF GEMCITABINE ;251 7.2.1;I. INTRODUCTION;251 7.2.2;II. PREPARATION OF GEMCITABINE PRODRUGS;253 7.2.3;III. ADVANTAGE OF CYCLOPROPYL ESTER PRODRUGS;255 7.2.4;IV. ISSUES WITH CYCLOPROPYL ESTERS OF GEMCITABINE;256 7.2.5;V. ALTERNATIVE PRODRUGS OF GEMCITABINE;257 7.2.6;VI. CO-CRYSTALS OF VALPROATE AMIDE OF GEMCITABINE;260 7.2.7;VII. STABILITY OF VALPROATE AMIDE PRODRUG;261 7.2.8;VIII. BIOAVAILABILITY OF AMIDE PRODRUG;262 7.2.9;IX. ANTITUMOR ACTIVITY OF PRODRUG;262 7.2.10;X. SUMMARY;263 7.2.11;References;263 7.3;7 ENZYMATICALLY ACTIVATED PHOSPHATE AND PHOSPHONATE PRODRUGS ;267 7.3.1;I. INTRODUCTION;267 7.3.2;II. PHOSPHATE GROUP USED FOR SOLUBILITY ENHANCEMENT;275 7.3.3;III. PHOSPHATE AND PHOSPHONATE PRODRUGS;277 7.3.4;IV. CONCLUSIONS;299 7.3.5;References;300 8;PART C ENZYMES POWERFUL WEAPONS FOR CORRECTING NATURE S ERRORS ;315 8.1;8 TREATMENT OPTIONS FOR MUCOPOLYSACCHARIDOSIS TYPE II (HUNTERS SYNDROME) ;317 8.1.1;I. INTRODUCTION;317 8.1.2;II. HISTORY;318 8.1.3;III. BIOCHEMISTRY;319 8.1.4;IV. GENETICS;321 8.1.5;V. CLINICAL MANIFESTATION;321 8.1.6;VI. MANAGEMENT AND TREATMENT;322 8.1.7;VII. FUTURE PERSPECTIVES;328 8.1.8;References;330 8.2;9 ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE ;335 8.2.1;I. INTRODUCTION;335 8.2.2;II. THE STRUCTURE AND CATALYTIC MECHANISMS OF HUMAN ALPHA-GALACTOSIDASE A;337 8.2.3;III. INTRACELLULAR METABOLISM AND LYSOSOMAL TARGETING OF HUMAN a-GALACTOSIDASE A;338 8.2.4;IV. RECOMBINANT HUMAN a-GALS AND PRINCIPLES OF ENZYME REPLACEMENT THERAPY;339 8.2.5;V. PHARMACOKINETICS, SAFETY, AND EFFICACY OF RECOMBINANT HUMAN a-GAL;341 8.2.6;VI. IMMUNE RESPONSE AND TOLERANCE;343 8.2.7;VII. TYPES OF DIFFERENT ENZYMATIC PREPARATIONS AND OTHER ENZYMES ON THE HORIZON;344 8.2.8;VIII. CONCLUSIONS;345 8.2.9;Refer
ences;346 8.3;10 METHODS AND PRINCIPLES OF PANCREATIC FUNCTION TESTS ;349 8.3.1;I. INTRODUCTION;349 8.3.2;II. TESTING OF PANCREATIC EXOCRINE FUNCTION;350 8.3.3;III. SUMMARY;352 8.3.4;References;352 9;INDEX;355 10;SUPPLEMENTARY IMAGES;359